© 2011 Dannemann Siemsen. Todos os direitos reservados. Biotech IP issues in Brazil Gustavo Morais May 2011 Gustavo Morais May 2011.

Slides:



Advertisements
Similar presentations
Chuck Schmal Patent & Trademark Attorney
Advertisements

Ethical aspects and Patents in Lifescience Peter R. Thomsen Manager Global IP Litigation, Corporate Intellectual Property, Novartis WIPO symposium on IP.
September 21, 2006 DePaul University, Chicago, IL APLF- DePaul University College of Law 2006 Symposium on Intellectual Property Law.
The Intellectual Property Rights Regime in India & US: The Evolving Landscape February 15, 2014, The Hyatt Regency Hotel, New Delhi D. CALAB GABRIEL.
Institut der beim Europäischen Patentamt zugelassenen Vertreter Institute of Professional Representatives before the European Patent Office Institut des.
Industrial Property the Patent system
Intellectual Property Rights (IPR)
Although humans have used biotechnology for thousands of years, discoveries made in the 1960s and 1970s increased our understanding about cells and molecules,
Antibody Patents in India Pravin Anand 14 th October 2011 Anand and Anand.
Patent protection of biotechnology inventions in Brazil Leonor Galvão de Botton, Ph.D. AIPLA Webinar June 27, 2013.
© 2011 Leonardos & Licks Latest Developments of the Brazilian Patent System Prepared for the 2011 Tongji Global Intellectual Property Forum Otto Licks.
“REACH-THROUGH CLAIMS”
BIOLOGICAL AND PHARMACEUTICAL PATENTS IN MEXICO Ing. Eugenio Pérez.
Intellectual Property, Free Trade Agreements and sustainable Development Hanan Sboul Secretary General/ The Jordanian Association of Pharmaceutical Manufacturers.
1 Unity of Invention: Biotech Examples TC1600 Special Program Examiner Julie Burke (571)
Costa Rica Pharma and Biotech Patent Update AIPLA Spring Meeting Seattle, Washington May 2013 Costa Rica Luis Diego Castro Castro.
Pre-AP Biology Ch.12 Ms. Haut
EPIP 2 Research Tools in Genetics Sandy Thomas Nuffield Council on Bioethics November 2003.
TRIPS Flexibilities Preventive Measures Johanna von Braun, PhD University of Cape Town, South Africa Kiev, 21/22 nd June, 2010.
W HAT CAN BE PATENTED – AND WHAT DOES THAT MEAN ? András Jókúti Hungarian Intellectual Property Office Ankara, 25 January 2011.
INTELLECTUAL PROPERTY PROTECTION OF BIOTECH IN THE U.S. Marc S. Friedman Chair, Intellectual Property Practice Sills Cummis Epstein & Gross P.C. 30 Rockefeller.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA PROPOSED PATENT BILL AND ITS RELEVANCY.
Biotech Inventions in Latin America Argentina Ignacio Sánchez Echagüe Marval, O’Farrell & Mairal.
“Inventing the Future” – The Role of Utility Models and Patents in Leveraging Technical Innovation in the Market Place Kingston, Jamaica Jun 4 - 6, 2012.
Page 1 IOP Genomics Workshop Patents and Patenting Biotech Inventions Annemieke Breukink, Ph.D. September 8th, 2009.
Impact of Myriad Decisions on Patent Eligibility of Biotechnology Inventions in Australia and the US.
Intellectual Property, Patents & Technology Transfer Sagar Manoli Shashidhar, Philippe Abdel-Sayed Responsible Conduct in Biomedical Research EPFL,
U.S. Patent and Trademark Office Technology Center 1600 Michael P. Woodward Unity of Invention: Biotech Examples.
IBT – Problem 9.3 TRIPS and Pharmaceutical Victor H. Bouganim WCL, American University.
EXCLUSIVE MARKETING RIGHTS & MAIL-BOX APPLICATIONS BY Manish Kumar Prusty T. Harish.
Developing an International IP Strategy that Includes Biotherapeutic Technologies Jerry L. Hefner SABPA 7th Annual Pacific Forum November 12, 2011.
Introduction to Patents Anatomy of a Patent & Procedures for Getting a Patent Margaret Hartnett Commercialisation & IP Manager University.
Session 6 : An Introduction to the TRIPS Agreement UPOV, 1978 and 1991 and WIPO- Administered Treaties.
Patents Business of Biotechnology BIT 120. Definition Patent Government grants which provide inventors with right to exclude others from practicing invention.
O VERVIEW OF P UBLIC H EALTH -R ELATED TRIPS F LEXIBILITIES Sisule F. Musungu, IQsensato (
Case 428/08 Monsanto v Cefetra e.a THE FUTURE OF BIOTECH PATENT PROTECTION IN EUROPE What every biotech patent practitioner should know John J. Allen.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA PROPOSED PATENT BILL AND ITS RELEVANCY.
Patentability of Reach-Through Claims Brian R. Stanton Practice Specialist Technology Center 1600 (703)
A: Copy –Rights – Artistic, Literary work, Computer software Etc. B: Related Rights – Performers, Phonogram Producers, Broadcasters etc. C: Industrial.
Intellectual Property Rights and Pharmaceutical Industry
Patent Protection of Biotechnological Inventions in China Gesheng Huang Partner Zhongzi Law Office AIPLA Spring Meeting, May 12-14, 2011, San Francisco,
No Incentive To Innovator Prior To 1st January 2005 Prior to 1st January 2005, the Indian Patent Act (1970) allowed only for process patents in all areas.
Protection of biotechnology innovations in Brazil Leonor Galvão de Botton, Ph.D. AIPLA Spring Meeting May, 2013.
Examination Practice in Applications Presenting “Reach-Through Claims” George Elliott Practice Specialist Technology Center 1600
Myriad The Future of DNA Claims Mercedes Meyer, Ph.D., JD AIPLA 1.
Patent Innovation Christine Chen 9/15/2008.  In general, patents must be:  Novel (not known previously) genetic sequences  Non-obvious (not just a.
An Overview of Intellectual Property by John Slaughter September 26, 2009 © John Slaughter All Rights Reserved.
PATENTS, INTEGRATED CIRCUITS, AND INDUSTRIAL DESIGNS Presented By: Navdeep World Trade Organization.
Introduction The Patentability of Human Genes Is patenting human genes moral? Should it be legal? Should there be international intervention?
Biotechnology Foundations of Technology Standard 15 Students will develop an understanding of and be able to select and use agricultural and related biotechnologies.
VISHAAL HARISARAN Intellectual Property Rights in Animal Breeding and Genetics.
INTRODUCTORY TO BIOTECHNOLOGY MCB 211 LECTURERS Dr Akintokun, A.K., Dr Balogun, S.O Dr Oluwafemi F.
Patents 101 March 28, 2006 And now, for something new, useful and not obvious.
EPICentre Legal Workshop Series: Biotechnology and IP Presented to: Entrepreneurship Practice & Innovation Centre, September 20, 2016 Presented by: Jenna.
Ip4inno 1 Content of the module IP for the creative industries Patented computer-implemented inventions Software Biotechnological inventions.
AIPLA Spring Meeting, Houston Texas
Overview of presentation
Intellectual Property & Contemporary Issues of Biotechnology Law
Intellectual Property, Free Trade Agreements and sustainable Development Hanan Sboul Secretary General/ The Jordanian Association of Pharmaceutical Manufacturers.
The Challenge of Biotech Patent Eligibility in the United States:
Patenting Biotechnology in Japan and recent hot issues
Ahmedabad, November 26, 2006 Kiyoshi Kuzuwa Patent Attorney
INTELECTUAL PROPERTY RIGHTS
Patent law update.
Patents, Cannabis, and the Current U.S. Climate
GENERAL INTRODUCTION THE PATENT SYSTEM.
Gene Patenting Connecticut Invention Convention
Examination Practice in Applications Presenting “Reach-Through Claims”
Patentable Subject Matter in Korea
Presentation transcript:

© 2011 Dannemann Siemsen. Todos os direitos reservados. Biotech IP issues in Brazil Gustavo Morais May 2011 Gustavo Morais May 2011

© 2011 Dannemann Siemsen. Todos os direitos reservados. 2 Brazil - Patents Changing scenario  No pharmaceutical and agrochemical patents (products) as of 1945 (processes excluded as of 1969)  No provisions concerning living matter  TRIPS - Jan 1, 1995  IP Law Nº 9,279 of May 14, 1996 (IPL)  No pharmaceutical and agrochemical patents (products) as of 1945 (processes excluded as of 1969)  No provisions concerning living matter  TRIPS - Jan 1, 1995  IP Law Nº 9,279 of May 14, 1996 (IPL)

© 2011 Dannemann Siemsen. Todos os direitos reservados. 3  Agrochemical patents  Patentability of GM microorganisms and of several inventions involving living matter  Waive of transition periods  Pipeline patents  Criteria for damage calculation  Agrochemical patents  Patentability of GM microorganisms and of several inventions involving living matter  Waive of transition periods  Pipeline patents  Criteria for damage calculation

© 2011 Dannemann Siemsen. Todos os direitos reservados. 4  Preliminary injunctions  Civil and criminal penalties against infringers  Infringement by equivalency  Patent term: 20 years as of filing or 10 years from grant, whichever expires later  Problem: ANVISA’s intervention – pharmaceutical products and processes  Preliminary injunctions  Civil and criminal penalties against infringers  Infringement by equivalency  Patent term: 20 years as of filing or 10 years from grant, whichever expires later  Problem: ANVISA’s intervention – pharmaceutical products and processes

© 2011 Dannemann Siemsen. Todos os direitos reservados. 5  Patentability criteria  Novelty  Inventive step  Industrial applicability  Enablement  Brazil not a member of Budapest Treaty  Biological material may be filed in any IDA  Patentability criteria  Novelty  Inventive step  Industrial applicability  Enablement  Brazil not a member of Budapest Treaty  Biological material may be filed in any IDA Patent basics

© 2011 Dannemann Siemsen. Todos os direitos reservados. 6 Patents Subject matter  Not patentable :  Living beings and parts thereof, including cells even if modified  TRIPS 27.3(b) allows exclusion of patentability only “plants and animals”  Naturally occurring biological material (even if isolated, purified or synthesized) and natural biologic processes

© 2011 Dannemann Siemsen. Todos os direitos reservados. 7  Not patentable :  Therapeutic, surgical and diagnostic methods applied to human or animal bodies  Discoveries as opposed to inventions  Genetic Use Restriction Technologies (GURTs)  Crime to use, sell, register, patent and license  Not patentable :  Therapeutic, surgical and diagnostic methods applied to human or animal bodies  Discoveries as opposed to inventions  Genetic Use Restriction Technologies (GURTs)  Crime to use, sell, register, patent and license

© 2011 Dannemann Siemsen. Todos os direitos reservados. 8  Patentable:  Microorganisms genetically modified through human intervention  Modified DNA/RNA sequences and genes  Considered as chemical compounds  Any process of genome modification  Patentable:  Microorganisms genetically modified through human intervention  Modified DNA/RNA sequences and genes  Considered as chemical compounds  Any process of genome modification

© 2011 Dannemann Siemsen. Todos os direitos reservados. 9  Patentable:  Chemical compositions characterized by its intrinsic features, even if including naturally occurring biological material  Processes for obtaining, isolating, modifying, manufacturing and using biological materials and living beings  Except humans (biosafety law)  Patentable:  Chemical compositions characterized by its intrinsic features, even if including naturally occurring biological material  Processes for obtaining, isolating, modifying, manufacturing and using biological materials and living beings  Except humans (biosafety law)

© 2011 Dannemann Siemsen. Todos os direitos reservados. 10 Polynucleotides e polypeptides  Allowable claims:  DNA sequence characterized by presenting... Sequence  DNA sequence characterized by being Seq. ID nº  Recombinant protein characterized by being Seq. ID nº  Not allowable claims:  DNA sequence characterized by codifying protein X  Protein characterized by presenting activity Y  Allowable claims:  DNA sequence characterized by presenting... Sequence  DNA sequence characterized by being Seq. ID nº  Recombinant protein characterized by being Seq. ID nº  Not allowable claims:  DNA sequence characterized by codifying protein X  Protein characterized by presenting activity Y

© 2011 Dannemann Siemsen. Todos os direitos reservados. 11 Polynucleotides e polypeptides  Naturally occuring biological material – not patentable  A composition including such material may be if its only distinctive feature is not the presence of of the material  Purifying and isolation methods - patentable  Naturally occuring biological material – not patentable  A composition including such material may be if its only distinctive feature is not the presence of of the material  Purifying and isolation methods - patentable

© 2011 Dannemann Siemsen. Todos os direitos reservados. 12 Antibodies  Patentable  Monoclonal antibody characterized by its hybridoma  Not patentable  Polyclonal antibodies since they considered a by-product of natural biological processes  Patentable  Monoclonal antibody characterized by its hybridoma  Not patentable  Polyclonal antibodies since they considered a by-product of natural biological processes

© 2011 Dannemann Siemsen. Todos os direitos reservados. 13 Methods of treatment and diagnosis  Not patentable per se  Swiss type claims  Patentable - methods of obtaining data outside the human or animal body such as measuring blood pressure, X-ray examination, hemograms, etc.  Not patentable - methods of diagnosis performed in the human or animal body (e.g, to determine an allergy)  Not patentable per se  Swiss type claims  Patentable - methods of obtaining data outside the human or animal body such as measuring blood pressure, X-ray examination, hemograms, etc.  Not patentable - methods of diagnosis performed in the human or animal body (e.g, to determine an allergy)

© 2011 Dannemann Siemsen. Todos os direitos reservados. 14 Stem cells  Not patentable per se  Patentable - methods of obtaining stem cells and using them, except if method of treatment or diagnosis  Not patentable per se  Patentable - methods of obtaining stem cells and using them, except if method of treatment or diagnosis

© 2011 Dannemann Siemsen. Todos os direitos reservados. 15 IP in agriculture  Plants not patentable, even if GM  Only the genes  Plant variety protection  Examples of allowable claims:  Method of pest or weed control using certain agrochemicals and/or plants  Process to confer to plants resistance to XYZ pesticide  Plants not patentable, even if GM  Only the genes  Plant variety protection  Examples of allowable claims:  Method of pest or weed control using certain agrochemicals and/or plants  Process to confer to plants resistance to XYZ pesticide

© 2011 Dannemann Siemsen. Todos os direitos reservados. 16 Access to Brazilian biodiversity  Authorization to access GRs and associated TK  Indication of source in patent applications filed as of 2007  Components of genetic heritage x biological resources  Recent PTO office actions and fines imposed on companies  Authorization to access GRs and associated TK  Indication of source in patent applications filed as of 2007  Components of genetic heritage x biological resources  Recent PTO office actions and fines imposed on companies

© 2011 Dannemann Siemsen. Todos os direitos reservados. Thank you! Obrigado!